National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1970 No. 186

___________

 

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1970.*

WHEREAS it is provided by sub-section (4.) of section 101 of the National Health Act 1953-1970 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following additional drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1970, namely, the drugs and medicinal preparations inserted in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations by regulation 4 and the Third Schedule to these Regulations:

NOW THEREFORE I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1970.

Dated this twenty-sixth day of November, 1970.

Paul Hasluck

Governor-General.

By His Excellency’s Command,

Minister of State for Health.

__________

 

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on the first day of December, 1970.

First Schedule.

2.The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.

Second Schedule.

3.The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.

Third Schedule.

4.The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Third Schedule to these Regulations.

Fourth Schedule.

5.The Fourth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended by omitting item 11.

Fifth Schedule.

6.The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Fourth Schedule to these Regulations.

_________________________________________________________________________________________________

* Notified in the Commonwealth Gazette on 1970.

  Statutory Rules 1960, No. 17, as amended by Statutory Rules 1960, Nos. 90 and 102; 1961, Nos. 59 and 137; 1962, Nos. 34, 101 and 114;1961, Nos. 34, 64 and 107; 1964, Nos. 12, 57 and 135; 1965 Nos. 51, 151 and 152; 1966, Nos. 80 and 141; 1967, Nos. 67, 116 and 158; 1968, Nos. 44, 76, 68 and 146; 1969, Nos. 44, 107 and 185; and 1970, Nos. 39, 94 and 119.

24542/70—Price 10c 10/16.11.1970

THE SCHEDULES

FIRST SCHEDULE Regulation 2.

Amendments of the First Schedule to the National Health (Pharmaceutical Benefits) Regulations

1 After item 4a insert—

“ 4b. Allopurinol ”.

2. After item 18 insert—

“ 18a. Azathioprine ”.

3. After item 20 insert—

“ 20a. Beclomethasone Dipropionate ”.

4. After item 26 insert—

“ 26a. Bethanidine Sulphate ”.

5. After item 30 insert—

“ 30a. Bupivacaine Hydrochloride ”.

6. After item 52a insert—

“ 52b. Chlormadinone Acetate ”.

7. After item 62 insert—

“ 62a. Chlortetracycline Hydrochloride ”.

8. Omit item 68, insert—

“ 68. Clofibrate ”.

9. Omit item 103a.

10. After item 105 insert—

“ 105a. Diazepam Capsules ”.

11. After item 114 insert—

“ 114a. Digitoxin Tablets

114b. Dihydrocodeine Injection

114c. Dihydrocodeine Tablets ”.

12. After item 129 insert—

“ 129a. Dried Human Albumin ”.

13. After item 131 insert—

“ 131a. Eltor Vaccine ”.

14. After item 134 insert—

“ 134a. Ethacrynic Acid ”.

15. After item 143a insert—

“ 143b. Ethynodiol Diacetate ”.

16. Omit items 149 and 158.

17. After item 161 insert—

“ 161a. Hexachlorophane ”.

18. After item 164 insert—

“ 164a. Human Albumin ”.

19. After item 187a insert—

“ 187b. Inulin

187c. Inulin Injection ”.

20. After item 206 insert—

“ 206a. Lithium Carbonate

206b. Lithium Carbonate Tablets ”.

21. After item 215 insert—

“ 215a. Mefenamic Acid

215b. Mefenamic Acid Capsules

215c. Megestrol Acetate ”.

22. Omit item 265.

23. Omit item 282, insert—

“ 282. Oxytetracycline Tablets ”.

24. After item 287 insert—

“ 287a. Penicillamine ”.

25. After item 296 insert—

“ 296a. Phenazocine Hydrobromide

296b. Phenazocine Injection

296c. Phenazocine Tablets ”.

26. After item 304 insert—

“ 304a. Phenoxybenzamine Capsules ”.

27. After item 370 insert—

“ 370a. Sodium Iodide (1251) Solution ”.

28. After item 407 insert—

“ 407a. Tetracycline Tablets ”.

29. After item 413 insert—

“ 413a. Tolnaftate ”.

30. After item 414 insert—

“ 414a. Tolazoline Tablets ”.

SECOND SCHEDULE  Regulation 3.

Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 39.

2. Add at the end of item 67 (in the third column)—

“ Oxyphenisatin Acetate with Dioctyl Sodium Sulphosuccinate, B.P.C.”.

3. Omit items 74 and 94.

4. Omit from item 105 “ Terric, N8 ” (in the third column), insert “ ‘TERIC’ N8 ”.

5. Omit item 133, insert—

“ 133	Nystatin..............................	Tetracycline, B.P.C. with a buffering agent and Nystatin
Demethylchlortetracycline with Nystatin
Tetracycline Hydrochloride with Nystatin
Gramicidin with Neomycin Sulphate, Triamcinolone Acetonide and Nystatin
Oxytetracycline Dihydrate with Nystatin ”.

6. After item 136 insert—

“ 136a Oxytetracycline Dihydrate .. Nystatin with Oxytetracycline Dihydrate ”.

7. Omit from item 137—

(a) “ Oxytetracycline Hydrochloride with a buffering agent and Nystatin ” (in the third column); and

(b)“ Oxytetracycline Hydrochloride with Nystatin ” (in the third column).

8. After item 137 insert—

“ 137a Oxyphenisatin Acetate......... Dioctyl Sodium Sulphosuccinate, B.P.C. with Oxyphenisatin Acetate ”.

9. After item 157 insert—

“ 157a Polyisobutylene.................... — ”.

10. After item 173 insert—

“ 173a Similac Isomil....................... — ”.

11. Omit item 184.

12. Omit item 193, insert—

“ 193	‘TERIC’ N8............................................	Cetrimide, with Spearmint Oil, B.P.C. and ‘TERIC’ N8
Lauryl Dimethylbenzyl Ammonium Chloride with ‘TERIC’ N8 ”.

THIRD SCHEDULE Regulation 4.

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. Omit item 15.

2. After item 27a insert—

“ 27b. Amitriptyline Embonate ”.

3. Omit items 38, 40, 52, 75, 90, 91, 96, 124, 127a, 137, 139, 140, 147, 160 and 163.

4. After item 164 insert—

“ 164a. Flurandrenolone Acetonide ”.

5. Omit items 183, 184, 195, 209, 232 and 239.

6. After item 244 insert—

“ 244a. Methylprednisolone Sodium Succinate ”.

7. Omit item 254.

8. After item 270 insert—

“ 270a. Oxyphenisatin Acetate ”.

9. Omit items 281 and 289.

10. After item 306a insert—

“ 306b. Polyisobutylene ”.

11. After item 319 insert—

“ 319a. Proscillaridin ”.

12. After item 341 insert—

“ 341a. Similac Isomil ”.

13. Omit items 355 and 364.

14. After item 368 insert—

“ 368a. Sulphasymazine ”.

15. Omit item 381, insert—

“ 381. ‘TERIC’ N8 ”.

16. Omit items 387, 398 and 410.

FOURTH SCHEDULE Regulation 6.

Amendments of the Fifth Schedule to the National Health (pharmaceutical benefits) regulations

1 Omit item 16.

2. Omit from item 24 (in the second column)—

“ (2) Betamethasone Sodium Phosphate Injection, B.P.”.

3. Insert in item 41, after—

“ Any disease or condition in a pensioner ” (in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

4. In item 42, add after—

“ A second or subsequent course of treatment for proven hyperbetalipoproteinaemia (type II) in patients who respond to treatment with cholestyramine but do not respond to other therapy ” (in the third column),

the words—

“ Bile salt malabsorption associated with ileal resection or proven ileal disease ”.

5. Insert in item 44, before—

“ With the written authority of the Director-General,” (in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

6. Omit from item 53 “ Terric N.8 ” (twice occurring in the second column), insert “ ‘TERIC’ N8 ”.

7. Omit item 56.

8. Insert in item 58, after—

“ Any disease or condition in a pensioner ” (in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

9. Insert in item 59, after—

“ Any disease or condition in a pensioner ” (in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

10. Insert in item 60, after—

“ Any disease or condition in a pensioner ” (in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

11. Omit item 63.

12. Omit from item 69 “ Dioctyl Sodium Sulphosuccinate with Danthron ” (in the second column), insert—

“ (1) Dioctyl Sodium Sulphosuccinate with Danthron

(2) Dioctyl Sodium Sulphosuccinate with Oxyphenisatin Acetate ”.

13. Omit item 71.

14. Insert in item 75, after—

“ Any disease or condition in a pensioner ” (in the third column),

the words—

“ Carcinoma of the breast, post menopausal ”.

15. Omit item 80.

16. Insert in item 83, before—

“T he treatment of a mental disorder in a person who ” (first occurring in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

17. Insert in item 84, after—

“ Any disease or condition in a pensioner ” (in the third column),

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

18. Insert in item 85, before—

“ Proven folic acid deficiency ” (in the third column),

the words—

“ Cystic fibrosis ”.

19. Insert in item 86, before—

“ Pregnancy ” (in the third column),

the words—

“ Cystic fibrosis ”.

20. Omit from item 95 “Griseofulvin Tablets, B.P.” (in the second column), insert—

“ (1) Griseofulvin, B.P.

(2) Griseofulvin Tablets, B.P.”.

21. Omit item 96.

22. Insert in item 98, after—

“ Any disease or condition in a pensioner ” (in the third column),

 the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

23. Omit item 99.

24. Omit from item 101 “ Stevens-Johnson disease ” (in the third column).

25. Omit item 111.

26. Omit from item 128 “ Treatment in neoplastic disease ” (in the third column), insert

“ Treatment in malignant neoplasia ”.

27. Omit from item 129 “ Treatment in neoplastic disease ” (in the third column), insert

“ Treatment in malignant neoplasia ”.

28. Add at the end of item 137 (in the third column) “ or where the patient is sensitive to sulphonamides ”.

29. In item 143, add after—

“ Encephalopathy, hepatic ” (in the third column),

the words—

“ Enteropathogenic E. coli infections in infants ”.

30. Omit item 145.

31. Add at the end of item 146 (in the third column) “ or where the patient is sensitive to sulphonamides ”.

32. After item 148 insert—

“ 148a	Norethisterone Tablets, B.P.....................	Endometriosis
Metrophathia haemorrhagica
Precocious puberty ”.

33. Omit item 151.

34. Omit from item 155 “ With the written authority of the Director-General, proven aplastic or hypoplastic anaemias (familial) ” (in the third column), insert—

“ With the written authority of the Director-General, proven aplastic anaemias ”.

35. Omit from item 157 “ Paracetamol Suspension ” (in the second column), insert “ Paracetamol mixture ”.

36. Omit item 160.

37. After item 166 insert—

“ 166a Polyisobutylene...................................... Ileostomy or colostomy conditions ”.

38. Omit from item 171 “ Stevens-Johnson disease ” (in the third column).

39. After item 176 insert—

“ 176a Proscillaridin.......................................... Patients intolerant of oral forms of prepared digitalis digoxin and lanatoside-C ”.

40. Add at the end of item 180 (in the third column)—

“ Proven pyridoxine responsive anaemia

With the written authority of the Director-General, primary hyperoxaluria ”.

41. After item 182 insert—

“ 182a	Similac Isomil.........................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years ”.

42. Omit item 186, insert—

“ 186	(1) Sodium Fusidate................................	With the written authority of the Director-General, the treatment of serious staphylococcal infections in a patient where it is, established by appropriate bacteriological testing that Sodium Fusidate or Diethanolamine Fusidate in combination with another antibiotic is an appropriate therapy ”.
(2) Diethanolamine Fusidate

43. Omit item 188.

44. Insert in item 189, before—

“ With the written authority of the Director-General— ”,

the words—

“ Primary hyperaldosteronism ”.

45. Insert in item 202, after—

“ Any disease or condition in a pensioner ”,

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

46. Omit item 205.

47. After item 207 insert—

“ 207a Triamcinolone Acetonide Injection........... With the written authority of the Director-General, treatment of keloids ”.

48. Insert in item 208, after—

“ Any disease or condition in a pensioner ”,

the words—

“ Any disease or condition in a patient receiving treatment in or at an approved hospital ”.

49. Omit item 212.

            

_________________

           

Printed by Authority by the Government Printer of the Commonwealth of Australia